BUDA JUICE, INC. (BUDA)

AI-Powered SEC Filing Analysis

Annual Report Filed: 2026-03-26

Key Insights

BUDA Juice's revenue was heavily concentrated in one customer, accounting for over 85% of total sales in both 2024 and 2025. This customer concentration risk poses a significant threat to the company's future performance.
The company has a financing agreement in place with an undisclosed lender, with the latest extension occurring in 2025. The terms and conditions of this agreement could impact BUDA's ability to access capital and fund its operations.
BUDA Juice plans to conduct an initial public offering (IPO) in 2026, which represents a key milestone for the company. The success of the IPO and subsequent public trading will be critical for the firm's long-term growth and shareholder value.

Current Report Filed: 2026-01-22

Key Insights

Buda Juice, Inc. announced the full exercise of the underwriters' over-allotment option, resulting in $2,999,992.50 in additional gross proceeds from the sale of 399,999 shares in the company's initial public offering.
The exercise of the over-allotment option indicates strong investor demand for Buda Juice's shares and suggests the IPO was well-received in the market.
The additional capital raised from the over-allotment option will provide Buda Juice with more resources to fund its growth and expansion plans as a newly public company.

Current Report Filed: 2026-01-09

Key Insights

Buda Juice, Inc. successfully completed a $20 million initial public offering, issuing 2,666,667 shares of common stock at $7.50 per share on the NYSE American exchange.
The company granted underwriters warrants to purchase an additional 266,667 shares, or 10% of the IPO shares, at an exercise price of $9.375 per share.
Buda Juice adopted a new 2025 Equity Incentive Plan to grant equity-based and cash-based awards to attract, motivate, and retain key employees, directors, and consultants.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.